PTC Therapeutics Full Year 2024 Earnings: Misses Expectations

PTC Therapeutics (NASDAQ:PTCT) Full Year 2024 Results

Key Financial Results

• Revenue: US$806.8m (down 14% from FY 2023).
• Net loss: US$363.3m (loss narrowed by 42% from FY 2023).
• US$4.73 loss per share (improved from US$8.37 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

PTC Therapeutics Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) also missed analyst estimates by 6.2%.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 9.0% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with PTC Therapeutics (at least 1 which doesn't sit too well with us), and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.